Pfizer's next-generation therapies for inflammatory bowel disease
Jeremy Gale leads Pfizer’s inflammation & immunology research program to develop new therapies for moderate to severe inflammatory bowel disease.
ulcerative colitis
Immune dysregulation in inflammatory bowel disease
Spatial biology platforms shed light on the cellular and molecular players underlying ulcerative colitis and Crohn’s disease.
